Cannabis Research Offers Hope for Alzheimer's Disease Symptom Management

In a recent webinar hosted by Dr. Dustin Sulak, a series of studies were highlighted, showcasing the potential role of cannabinoids in managing symptoms of Alzheimer's disease and cognitive decline. The November Healer webinar delved into both in vitro and in vivo research, providing insights into how cannabinoids might alleviate symptoms such as memory loss and cognitive impairment. Dr. Sulak also touched upon the implications of new federal legislation regarding hemp products, suggesting that it offers a window for developing more sensible regulations over the next year

One of the key studies discussed was published in the Journal of Alzheimer’s Disease in October 2025. This phase 2, randomized, double-blind, placebo-controlled trial involved 28 participants with Alzheimer's who were administered a low-dose THC-CBD extract over 26 weeks. The results were promising, showing that those who received the cannabinoid extract scored higher on cognitive assessments compared to the placebo group. Despite the small sample size, Dr. Sulak emphasized the significance of these findings, especially as they offer a more affordable alternative to existing treatments

Another study, published in Phytotherapy Research in January 2025, explored the effects of CBDA and CBGA on Alzheimer's disease progression. These cannabinoids were tested for their ability to inhibit enzymes associated with the disease, showing potential to improve cognitive function in rodent models. Dr. Sulak noted that these findings suggest a broader applicability of these compounds beyond just dementia, hinting at their potential in treating other neurological conditions

Further research, published in the International Journal of Molecular Sciences, examined the impact of CBDA on synaptic connections in Alzheimer's models. This study found that CBDA could reverse deficits in long-term potentiation, a process crucial for learning and memory. Dr. Sulak highlighted how these results underscore the importance of understanding upstream factors in Alzheimer's disease, such as mitochondrial function and protein management, and how cannabinoids might influence these processes

The potential for cannabinoids to manage behavioral symptoms of dementia was also reviewed in a systematic study published in the Journal of Psychopharmacology in October 2025. This review of ten studies involving 278 participants found that cannabinoids could effectively reduce agitation, improve sleep, and enhance caregiver satisfaction. These findings underscore the multifaceted benefits of cannabinoids, particularly in improving the quality of life for patients and their caregivers

Dr. Sulak concluded the webinar by emphasizing the urgent need for effective treatments for dementia, given the aging population and the economic burden of care. He pointed out that cannabis offers a promising avenue for developing cost-effective and safe treatments. The ongoing research into cannabinoids not only holds potential for alleviating symptoms of dementia but also for unlocking broader therapeutic applications, highlighting the need for continued exploration and clinical trials